CSE:NOVOB.CO 10 January 2026 - 9 February 2026

For live price, interactive charts, financials and the latest market data, visit Google Finance.

Novo Nordisk stock jumps 8% as Hims drops $49 semaglutide pill plan

Novo Nordisk climbed 8.3% to 320 Danish crowns in Copenhagen by 10:50 a.m. local time, after Hims & Hers scrapped plans for a $49 weight-loss pill made with compounded semaglutide—the same compound found in Novo’s Wegovy and Ozempic.

9 February 2026

CSE:NOVOB.CO·NASDAQ:HIMS·NYSE:LLY·Pharmaceuticals·Stock Market

Novo Nordisk Class B stock: what to watch after Hims pulls $49 Wegovy pill copy

Novo Nordisk A/S Class B starts the week with less pressure from copycat concerns, after Hims & Hers said it’s pulling its $49 compounded version of Novo’s Wegovy weight-loss pill. Novo, Hims & Hers, and Eli Lilly are also sinking serious money into Super Bowl ads, all trying to catch more cash-paying U.S. customers.

8 February 2026

CSE:NOVOB.CO·Health News·Pharmaceuticals·Stock Market

Novo Nordisk Class B stock jumps — Wegovy pill scripts and UK dose nod set up the week ahead

Novo Nordisk A/S Class B shares surged 6.49% on Friday, closing at 388.9 Danish crowns after hitting a high of 391.3 crowns during the session. The stock is set to reopen Monday, with traders reacting to the latest Wegovy news.

18 January 2026

CSE:NOVOB.CO·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Novo Nordisk Class B stock rises after Amazon adds Wegovy pill — what to watch before earnings

Novo Nordisk A/S Class B shares rose 3% on Friday after Amazon Pharmacy announced it had started selling the company’s Wegovy weight-loss pill, expanding availability for U.S. patients just days following the drug’s market debut. The Copenhagen-traded stock closed at 381.45 Danish crowns.

10 January 2026

CSE:NOVOB.CO·Pharmaceuticals·Stock Market

Go toTop